Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NAAA | Q02083 | 2/20 | 0.51 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.50 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30975296 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL7120698 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL477567 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL477546 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL477511 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL8193119 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL405975 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL477578 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL22491606 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E | |
| SCHEMBL29199312 | 1.00 | LMNA (0.59) | LMNAASAH1RIPK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0805825-B1 | GELS FROM ANHYDRIDE-CONTAINING POLYMERS | TYCO ELECTRONICS CORP (US) | 2000-08-23 | — | — | EP | claimed |
| US-5849824-A | Gels from anhydride-containing polymers | RAYCHEM CORPORATION (US) | 1998-12-15 | — | — | US | claimed |
| EP-0805825-A1 | GELS FROM ANHYDRIDE-CONTAINING POLYMERS | RAYCHEM CORPORATION (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996023007-A1 | GELS FROM ANHYDRIDE-CONTAINING POLYMERS | RAYCHEM CORPORATION (US) | 1996-08-01 | — | — | WO | claimed |
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-2412694-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-7112608-B2 | Hydroxyphenylundecane, a process for their production and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-09-26 | — | — | US | disclosed |
| US-7112608-B2 | Hydroxyphenylundecane, a process for their production and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-09-26 | — | — | US | disclosed |
| US-7112608-B2 | Hydroxyphenylundecane, a process for their production and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| CN-1055375-A | The copolymer compositions that contains multipolymer and one or more slip additives | SHELL INT RESEARCH (NL) | 1991-10-16 | — | — | CN | disclosed |
| EP-0450695-A1 | Copolymer compositions comprising a copolymer and one or more lubricating additives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-10-09 | — | — | EP | disclosed |
| US-4894480-A | Phenyl substituted-2,4,6,8-nonatetraenoic acid | HOFFMANN-LA ROCHE INC. (US) | 1990-01-16 | — | — | US | disclosed |
| US-4883614-A | TREATMENT OF RHEUMATOID ARTHRITIS, IMMUNOSUPPRESSANTS | HOFFMAN-LA ROCHE INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4883613-A | TREATMENT OF RHEUMATOID ARTHRITIS, IMMUNOSUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4780251-A | ANTIRHEUMATIC AGENTS, IMMUNOSUPPRESSANTS | HOFFMAN-LA ROCHE INC. (US) | 1988-10-25 | — | — | US | disclosed |
| US-4648996-A | ANTIRHEUMATIC AGENTS, IMMUNOSUPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | LMNA 1422/4885ASAH1 3422/4885RIPK1 4112/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | LMNA 2126/4885ASAH1 1503/4885RIPK1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.